Collegium Pharmaceutical
COLL
145 hedge funds and large institutions have $476M invested in Collegium Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 36 increasing their positions, 43 reducing their positions, and 17 closing their positions.
147% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 17
101% more call options, than puts
Call options by funds: $395K | Put options by funds: $197K
21% more funds holding
Funds holding: 120 → 145 (+25)
7.42% less ownership
Funds ownership: 101.64% → 94.22% (-7.4%)
16% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 43
18% less capital invested
Capital invested by funds: $580M → $476M (-$104M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$6.33M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$4.15M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.09M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.19M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$19.8M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$13.3M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$8.36M |
| 4 |
PA
Perceptive Advisors
New York
|
-$7.37M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$5.56M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
151
Landscape Capital Management
Englewood,
New Jersey
| – | -$349K | -20,309 | Closed |
|
152
AQR Capital Management
Greenwich,
Connecticut
| – | -$298K | -17,335 | Closed |
|
|
RJA
153
Raymond James & Associates
St Petersburg,
Florida
| – | -$227K | -13,216 | Closed |
|
|
OPERF
154
Oregon Public Employees Retirement Fund
Tigard,
Oregon
| – | -$103K | -6,000 | Closed |
|
|
QT
155
Quantbot Technologies
New York
| – | -$78K | -4,580 | Closed |
|
|
AG
156
Advisor Group
Phoenix,
Arizona
| – | -$58K | -3,400 | Closed |
|
157
US Bancorp
Minneapolis,
Minnesota
| – | -$42K | -2,449 | Closed |
|
|
CG
158
Cutler Group
San Francisco,
California
| – | -$25K | -1,500 | Closed |
|
|
SWM
159
SeaCrest Wealth Management
Purchase,
New York
| – | -$26K | -1,500 | Closed |
|
160
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$16K | -946 | Closed |
|
|
AIC
161
Ameritas Investment Company
Lincoln,
Nebraska
| – | -$9K | -500 | Closed |
|
|
MWNA
162
Marshall Wace North America
New York
| – | +$224 | +14 | New |
|
COLL Hedge Fund Activity: Q1 2019 in Review
145 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2019, worth a combined $476M — down 18% from $580M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new COLL positions and 17 closed out — a net gain of 25 holders — while 36 added to existing stakes and 43 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $6.33M. The largest seller was Millennium Management, cutting an estimated $19.8M.
- 145 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2019, up from 120 in Q4 2018.
- Funds reported $476M of Collegium Pharmaceutical stock for Q1 2019, down 18% quarter-over-quarter.
- 42 funds opened new Collegium Pharmaceutical positions in Q1 2019 and 17 closed out, a net change of +25 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2019 was Maverick Capital, an estimated $6.33M added.
- The largest Collegium Pharmaceutical seller in Q1 2019 was Millennium Management, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2019.